跳至主要内容
临床试验/EUCTR2016-001010-17-GB
EUCTR2016-001010-17-GB进行中(未招募)1 期

ucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance. (NUC-B) - Nucleos(t)ide withdrawal in Hepatitis B virus infection (NUC-B)

Imperial College, London0 个研究点目标入组 0 人开始时间: 2016年7月13日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Chronic HBV infection
  • HBeAg negative
  • Nucleos(t)ide analogues treatment for =3 years
  • HBV DNA < 400 IU/ml =2 years
  • Informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 240
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • Cirrhosis at any time
  • HBeAg to anti-HBe seroconversion within the last 3 years
  • Interferon use in the last 3 years
  • Contraindications to interferon use
  • Participation in HBV-specific therapeutic vaccine studies within 12 months
  • HCV, HDV or HIV co-infection
  • Immunosuppressant use
  • Clinically significant comorbidities that, in the opinion of the investigator, render the patient unsuitable.

研究者

相似试验